The Journal of family practice
-
Quadrivalent human papillomavirus vaccine against the viral types most likely to cause cervical cancer (types 16 and 18) and genital warts (types 6 and 11) has been licensed in the United States. The vaccine is 95% to 100% efficacious against cervical intraepithelial neoplasia and adenocarcinoma in situ and 99% efficacious against genital warts caused by serotypes in the vaccine. ⋯ Routine vaccination of females at 11 to 12 years of age is recommended. Catch-up vaccination is recommended for females age 13 to 26 years who have not yet been vaccinated, and vaccination of girls 9 and 10 years of age is permitted at the discretion of the physician.